Important News
1. The China Nonferrous Metals Industry Association firmly opposes "involutionary" competition in the copper smelting industry.
2. The Ministry of Commerce has added three US companies to the Unreliable Entity List and three US entities to the Export Control List.
3. The Ministry of Commerce stated that all countries should jointly oppose all forms of unilateralism and protectionism, and must not sacrifice the interests of third parties due to coercion from others.
4. The total size of public funds has exceeded 36 trillion yuan, reaching a record high for the fifth time this year.
Individual Stock News
1. Shangwei New Materials is suspended for investigation today. Its stock price has risen by over 1,800% this year, with 15 instances of abnormal fluctuation.
2. Ganfeng Lithium: Its controlling subsidiary Ganfeng Lithium plans to introduce investors to increase its capital by no more than 2.5 billion yuan.
3. Jingfeng Mingyuan: Its second-generation DrMos chip has been adopted by multiple customers and has entered mass production.
4. Pingmei Group: Its controlling shareholder, China Pingmei Shenma Holding Group, is undergoing a strategic restructuring, and its production and operations will not be significantly affected. 5. Lutian Machinery: No affiliation or business cooperation exists with Zhuhai Lutian Machinery Co., Ltd.
6. Xiamen International Trade: Participating investment funds hold a 0.67% stake in Moore Thread.
7. Yuexiu Capital: Moore Thread is an investment project of Yuexiu Industrial Fund Management.
8. Great Wisdom: The A-share exchange price of Xiangcai Holdings is 7.51 yuan per share, while the A-share exchange price of Great Wisdom is 9.53 yuan per share.
9. Putailai: We have delivered dry-process and solid-state battery electrode equipment to leading domestic and international customers.
10. Handler: Apple's launch of new models, which are both in high demand and in high production, has accelerated the upgrade of equipment related to its mobile phone production lines. Related products of our investment company have entered the proof-of-concept stage.
11. Hanyu Pharmaceutical: Plans to raise up to 968 million yuan through a private placement to fund semaglutide research and development projects, including the domestically marketed injectable form and the US-marketed oral tablet form. 12. Taienkang: CKBA Cream, a controlled subsidiary, has received approval for clinical trials for the rosacea indication. No innovative Class 1 drug for the treatment of rosacea has been approved for marketing in China.
13. Baili Tianheng: Iza-bren (EGFR×HER3 dual-antibody ADC), the world's first innovative drug and the only one to enter Phase III clinical trials, has received another indication for Breakthrough Therapy Designation.
